Le Lézard
Classified in: Health
Subject: OFR

Inhibikase Therapeutics Announces Closing of Initial Public Offering

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the closing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase, were $18 million. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of Inhibikase's common stock at the initial public offering price, less underwriting discounts and commissions.

Inhibikase's common stock began trading on the Nasdaq Capital Market on December 23, 2020 under the ticker symbol "IKT."

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on December 22, 2020. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at prospectus@think-equity.com. These documents may also be obtained free of charge, when they are available, by visiting the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Inhibikase (www.inhibikase.com
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Investor Relations:
Milton H. Werner, PhD
President & CEO, Inhibikase

Mary Moynihan
M2Friend Biocommunications


SOURCE Inhibikase Therapeutics

These press releases may also interest you

at 06:05
Cybin Inc. (NEO:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, today announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). Cybin will...

at 06:00
The third annual Green Shirt Day is one month away. Leading up to Green Shirt Day on April 7, the Canadian Transplant Association, the Kidney Foundation of Canada, Canadian Blood Services and Canada's organ and tissue donation community are asking...

at 06:00
Based on Global Market Insights Inc., report, the global Stilbene Market size was estimated at $1.8 billion in 2019 and is slated to surpass $3 billion by 2026, registering a CAGR of 7.5% from 2020 to 2026 primarily owing to increasing demand for...

at 06:00
SVB Leerink, a leading investment bank specializing in healthcare and life sciences, announced today that Robert Minear will join the firm's Healthcare Services and Technology Franchise team. Mr. Minear will be based in SVB Leerink's New York office...

at 06:00
The leading medical research publisher and nonprofit PLOS has published a new study that shows the safety and efficacy of bariatric surgery for patients with obesity and severe type 2 diabetes. Although there is a wide consensus in the global...

at 05:30
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of inherited retinal diseases, today announced that its President, Samarendra Mohanty, Ph.D., will participate in the Association for Ocular...

News published on 28 december 2020 at 10:33 and distributed by: